Direxion's Eli Lilly-Focused Bull And Bear Funds Offer Speculative Alternatives

1. Eli Lilly remains resilient amid economic challenges in healthcare. 2. Obesity drug orforglipron shows positive phase 3 results for type 2 diabetes. 3. LLY's current valuation at 71 times earnings raises investor concerns. 4. Trading options signal enthusiasm but share price is high at $800. 5. Historical trends indicate LLY stock may rise in the near term.